Liver transplantation in treatment of hepatocellular carcinoma: management of whole⁃process and progress in treatment

Abstract

CLC Number:

FENG Hao, LÜ Zicheng, XIA Qiang. Liver transplantation in treatment of hepatocellular carcinoma: management of whole⁃process and progress in treatment[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 119-122.

References21

[1]	Kardashian A, Florman SS, Haydel B, et al. Liver transplantation outcomes in a U.S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond milan criteria[J]. Hepatology, 2020, 72(6):2014-2028. doi:10.1002/hep.31210 URL
[2]	Ziogas IA, Giannis D, Economopoulos KP, et al. Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates[J]. Transplantation, 2021, 105(10):2263-2271. doi:10.1097/TP.0000000000003539 URL
[3]	Giannis D, Sideris G, Kakos CD, et al. The role of liver transplantation for colorectal liver metastases: a systema-tic review and pooled analysis[J]. Transplant Rev (Orlando), 2020, 34(4):100570.
[4]	Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review[J]. Surgery, 2017, 162(3):525-536. doi:10.1016/j.surg.2017.05.006 URL
[5]	Sapisochin G, Hibi T, Toso C, et al. Transplant oncology in primary and metastatic liver tumor: principles, evidence and opportunities[J]. Ann Surg, 2021, 73(3):483-493.
[6]	冯浩, 夏强. 肝移植与肿瘤:发展、机遇与挑战[J]. 中华器官移植杂志, 2021, 42(2):65-67.
[7]	Benson AB, D′Angelica MI, Abbott DE, et al. Hepatobi-liary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565. doi:10.6004/jnccn.2021.0022 URL
[8]	Jia AY, Popovic A, Mohan AA, et al. Development, practice patterns, and early clinical outcomes of a multidisciplinary liver cancer clinic[J]. Cancer Control, 2021, 28:10732748211009945.
[9]	张子杰, 乔子耘, 冯浩, 等. 系统治疗在肝癌术前新辅助治疗中应用进展[J]. 中国实用外科杂志, 2021, 41(3):326-331.
[10]	Kardashian A, Florman SS, Haydel B, et al. Liver transplantation outcomes in a US multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond Milan criteria[J]. Hepatology, 2020, 72(6):2014-2028. doi:10.1002/hep.31210 URL
[11]	Cambridge WA, Fairfield C, Powell JJ, et al. Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma[J]. Ann Surg, 2021, 273(2):240-250. doi:10.1097/SLA.0000000000003801 URL
[12]	Potter W, Davidi S, Jacobovitch S, et al. Tumor treating fields (TTFields) in combination with sorafenib inhibit hepatocellular carcinoma in vitro and in vivo[J]. J Clin Oncol, 2022, 40(4 suppl):464-464.
[13]	Zhang YF, Guo RP, Zou RH, et al. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study[J]. Eur Radiol, 2016, 26(7):2078-2088. doi:10.1007/s00330-015-4021-8 URL
[14]	Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation[J]. Hepatology, 2007, 45(2):269-276. doi:10.1002/hep.21465 URL
[15]	Han B, Ding H, Zhao S, et al. Potential role of adjuvant lenvatinib in improving disease-free survival for patients with high-risk hepatitis B virus-related hepatocellular carcinoma following liver transplantation: a retrospective, case control study[J]. Front Oncol, 2020, 10:562103.
[16]	Chen YY, Chen CL, Lin CC, et al. Efficacy and safety of lenvatinib in hepatocellular carcinoma patients with liver transplantation: a case-control study[J]. Cancers (Basel), 2021, 13(18):4584. doi:10.3390/cancers13184584 URL
[17]	European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. doi:10.1016/j.jhep.2018.03.019 URL
[18]	Zhou B, Shan H, Zhu KS, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation[J]. J Vasc Interv Radiol, 2010, 21(3):333-338. doi:10.1016/j.jvir.2009.11.006pmid:20116286
[19]	Ko HK, Ko GY, Yoon HK, et al. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation[J]. Korean J Radiol, 2007, 8(4):320-327. doi:10.3348/kjr.2007.8.4.320 URL
[20]	Au KP, Chiang CL, Chan ACY, et al. Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation[J]. World J Clin Cases, 2020, 8(13):2758-2768. doi:10.12998/wjcc.v8.i13.2758 URL
[21]	Walburn T, Moon AM, Hayashi PH, et al. Stereotactic body radiation therapy for recurrent, isolated hepatocellular carcinoma lymph node metastasis with or without prior liver transplantation[J]. Cureus, 2020, 12(8):e9988.

Liver transplantation in treatment of hepatocellular carcinoma: management of whole⁃process and progress in treatment

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References21

Related Articles15

Recommended Articles

Metrics

Comments

[1]	YE Feng, GONG Xiaoyong, REN Jiajun, CAI Qiang, CHEN Sheng.Application of ERCP in diagnosis and treatment of biliary complications during perioperative period of primary liver cancer[J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 355-360.
[2]	CHANG Jessica, CHEN Xuxiao, CHEN Yongjun.Role of the spleen in patients with liver cancer and cirrhosis[J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 394-398.
[3]	ZHANG Hui, GONG Ling, GUO Qian, LUO Yan.Retrospective study on sugammadex for reversal of neuromuscular blockade after radiofrequency ablation of hepatic carcinoma under general anesthesia[J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 72-76.
[4]	ZHANG Jixiang, XIE Zhihua, LI Wei, JIANG Xiaoqing.Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment[J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 478-482.
[5]	YIN Yanjiang, LUO Zhiwen, CHEN Xiao, ZHANG Yefan, HUANG Zhen, ZHAO Hong, ZHAO Jianjun, LI Zhiyu, ZHOU Jianguo, CAI Jianqiang, BI Xinyu.Relationship between surgical margin and prognosis of patients with intrahepatic cholangiocarcinoma[J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 221-228.
[6]	CHEN Congyan, WANG Junqing, CHEN Yongjun.Gut microbiota and mechanism of liver cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 256-260.
[7]	HUANG Jiwei, QIU Guoteng, ZENG Yong.Advances in surgical treatment of hepatocellular carcinoma[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 113-118.
[8]	FANG Cheng, XIA Yong, WANG Kui, SHEN Feng.Conversion therapy for intrahepatic cholangiocarcinoma: status and perspectives[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 107-112.
[9]	LIU Shenyang, TANG Zhaohui, QUAN Zhiwei.Advances in surgical treatment of intrahepatic cholangiocarcinoma[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 100-106.
[10]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 93-94.
[11]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 95-99.
[12]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 123-127.
[13]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 128-130.
[14]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 131-133.
[15]	.[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 134-138.